S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Arcadia Biosciences Stock Price, Forecast & Analysis (NASDAQ:RKDA)

$4.14
-0.04 (-0.96 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$3.95
Now: $4.14
$4.22
50-Day Range
$4.07
MA: $4.78
$6.02
52-Week Range
$1.82
Now: $4.14
$10.40
Volume584,800 shs
Average Volume1.32 million shs
Market Capitalization$35.79 million
P/E RatioN/A
Dividend YieldN/A
Beta-3
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. Read More…

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Current SymbolNASDAQ:RKDA
CUSIPN/A
Phone530-756-7077

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.46 million
Book Value$2.68 per share

Profitability

Net Income$-13,480,000.00
Net Margins-1,938.76%

Miscellaneous

Employees44
Market Cap$35.79 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive RKDA News and Ratings via Email

Sign-up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.


Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Arcadia Biosciences's stock reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences Inc (NASDAQ:RKDA) released its quarterly earnings data on Wednesday, November, 6th. The basic materials company reported ($2.04) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $1.27. The basic materials company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.31 million. Arcadia Biosciences had a negative return on equity of 198.10% and a negative net margin of 1,938.76%. View Arcadia Biosciences' Earnings History.

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Arcadia Biosciences.

What price target have analysts set for RKDA?

2 Wall Street analysts have issued 1-year target prices for Arcadia Biosciences' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Arcadia Biosciences' stock price to reach $17.00 in the next year. This suggests a possible upside of 310.6% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.

What is the consensus analysts' recommendation for Arcadia Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.

What are Wall Street analysts saying about Arcadia Biosciences stock?

Here are some recent quotes from research analysts about Arcadia Biosciences stock:
  • 1. National Securities analysts commented, " Second Quarter Results Meet Expectations. A $5.0 million operating loss fell in line with our $4.8 million estimates. GAAP earnings were skewed by a $9.5 million non-cash gain from warrant adjustments. Excluding this, earnings fell in line with estimates.
     Cannabis Initiative Taking Off. The story of the earnings release was surprisingly not what has driven volume in recent days. The cannabis initiative is accelerating faster than we anticipated, with the company now expecting to derive near term revenue from sale of seed. We estimate this high margin product could conservatively deliver $3 to $5 million of revenue in 2020, with modest initial revenues coming in the fourth quarter of 2019.
     HB4 Approved By USDA. On August 8th, the USDA announced its approval of the HB4 soybean to be grown domestically. This is a meaningful milestone and came 12 to 24 months before we anticipated. RKDA can now identify a commercial partner and integrate the trait into domestic germplasm with field trials likely to begin in 2021 and commercial revenue in 2023. While this is a faster timeline than we expected, it does not significantly alter our estimates or valuation.
     Cannabis Value Still In Early Innings. We believe the most valuable revenue in agribusiness is derived from proprietary genetics, and we believe the most valuable crop in the market is cannabis. RKDA is engaged in breeding efforts to develop proprietary lines of cannabis, which we believe is a roughly 3 year process before commercialization can begin. For patient investors, we believe RKDA is in the process of generating significant value via these efforts, and we expect enhanced visibility of this potential over the next 12 to 24 months." (8/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $140M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend. This translates into a price per share of $14.00, assuming roughly 10M shares outstanding as of end-1Q20." (6/6/2019)
  • 3. According to Zacks Investment Research, "Arcadia Biosciences, Inc. is engaged in developing and commercializing agricultural products primarily in the United States. The Company's product includes nitrogen use crops, salt tolerant plants, sunflower oil and shelf-life produce. Arcadia Biosciences, Inc. is headquartered in Davis, California. " (2/14/2019)

Has Arcadia Biosciences been receiving favorable news coverage?

Headlines about RKDA stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcadia Biosciences earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the basic materials company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Arcadia Biosciences.

Who are some of Arcadia Biosciences' key competitors?

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Micron Technology (MU), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Opko Health (OPK), Viking Therapeutics (VKTX), Verastem (VSTM) and Anavex Life Sciences (AVXL).

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the folowing people:
  • Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)
  • Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)
  • Ms. Sarah Reiter, Chief Commercial Officer (Age 47)
  • Dr. Randy Shultz Ph.D., Head of R&D
  • Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53)

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $4.14.

How big of a company is Arcadia Biosciences?

Arcadia Biosciences has a market capitalization of $35.79 million and generates $1.46 million in revenue each year. The basic materials company earns $-13,480,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe.View Additional Information About Arcadia Biosciences.

What is Arcadia Biosciences' official website?

The official website for Arcadia Biosciences is http://www.arcadiabio.com/.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]


MarketBeat Community Rating for Arcadia Biosciences (NASDAQ RKDA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  185 (Thanks for Voting!)
Underperform Votes:  180 (Thanks for Voting!)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote "Outperform" if you believe RKDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: What is a Call Option?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel